Mesoblast Limited (ASX:MSB)

Mesoblast Statistics

Total Valuation

Mesoblast has a market cap or net worth of AUD 2.59 billion. The enterprise value is 2.53 billion.

Market Cap	2.59B
Enterprise Value	2.53B

Important Dates

The last earnings date was Wednesday, August 27, 2025.

Earnings Date	Aug 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Mesoblast has 1.28 billion shares outstanding. The number of shares has increased by 22.41% in one year.

Current Share Class	1.28B
Shares Outstanding	1.28B
Shares Change (YoY)	+22.41%
Shares Change (QoQ)	+11.47%
Owned by Insiders (%)	37.27%
Owned by Institutions (%)	24.91%
Float	787.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	98.56
PB Ratio	2.84
P/TBV Ratio	66.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-16.27
EV / Sales	96.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-32.82

Financial Position

The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.21.

Current Ratio	1.99
Quick Ratio	1.72
Debt / Equity	0.21
Debt / EBITDA	n/a
Debt / FCF	-2.53
Interest Coverage	-2.87

Financial Efficiency

Return on equity (ROE) is -18.95% and return on invested capital (ROIC) is -5.89%.

Return on Equity (ROE)	-18.95%
Return on Assets (ROA)	-5.37%
Return on Invested Capital (ROIC)	-5.89%
Return on Capital Employed (ROCE)	-9.16%
Revenue Per Employee	323,853
Profits Per Employee	-1.92M
Employee Count	73
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

In the past 12 months, Mesoblast has paid 503,349 in taxes.

Income Tax	503,349
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +96.12% in the last 52 weeks. The beta is 1.32, so Mesoblast's price volatility has been higher than the market average.

Beta (5Y)	1.32
52-Week Price Change	+96.12%
50-Day Moving Average	2.13
200-Day Moving Average	2.15
Relative Strength Index (RSI)	35.43
Average Volume (20 Days)	3,563,632

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mesoblast had revenue of AUD 26.23 million and -155.80 million in losses. Loss per share was -0.13.

Revenue	26.23M
Gross Profit	-34.68M
Operating Income	-95.24M
Pretax Income	-155.29M
Net Income	-155.80M
EBITDA	-88.75M
EBIT	-95.24M
Loss Per Share	-0.13

Balance Sheet

The company has 246.41 million in cash and 195.48 million in debt, giving a net cash position of 50.94 million or 0.04 per share.

Cash & Cash Equivalents	246.41M
Total Debt	195.48M
Net Cash	50.94M
Net Cash Per Share	0.04
Equity (Book Value)	911.28M
Book Value Per Share	0.71
Working Capital	155.16M

Cash Flow

In the last 12 months, operating cash flow was -76.19 million and capital expenditures -1.04 million, giving a free cash flow of -77.23 million.

Operating Cash Flow	-76.19M
Capital Expenditures	-1.04M
Free Cash Flow	-77.23M
FCF Per Share	-0.06

Margins

Gross Margin	-132.22%
Operating Margin	-363.08%
Pretax Margin	-592.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Mesoblast does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.41%
Shareholder Yield	n/a
Earnings Yield	-6.03%
FCF Yield	-2.99%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mesoblast has an Altman Z-Score of 2.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.45
Piotroski F-Score	5